Longeveron Announces Up To $17.5 Million Public Offering

Group 1 - Longeveron Inc. announced a public offering of 5,882,354 shares of Class A common stock at a price of $0.85 per share, with potential additional gross proceeds of up to $12.5 million from short-term warrants [1][3] - The offering is expected to close on or about August 11, 2025, subject to customary closing conditions [1] - The company intends to use the net proceeds for ongoing clinical and regulatory development of laromestrocel, including funding for various disease states such as HLHS, Alzheimer's disease, and pediatric DCM [3][6] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The securities are being offered under a registration statement filed with the SEC, which became effective on August 8, 2025 [4] Group 3 - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines, with its lead product being laromestrocel, an allogeneic mesenchymal stem cell therapy [6] - The company is pursuing four pipeline indications: HLHS, Alzheimer's disease, Pediatric DCM, and Aging-related Frailty, and has received multiple FDA designations for its development programs [6]